News Releases

All Releases
View Summary Johnson & Johnson to Webcast Annual Meeting of Shareholders
Mar 27, 2015
PDF 7.8 KB Add to Briefcase
View Summary Johnson & Johnson Announces Definitive Agreement To Collaborate With Google To Advance Surgical Robotics
Mar 27, 2015
PDF 9.9 KB Add to Briefcase
View Summary Janssen Acquires XO1 Limited
Mar 19, 2015
PDF 13.2 KB Add to Briefcase
View Summary Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
Mar 17, 2015
PDF 8.6 KB Add to Briefcase
View Summary Johnson & Johnson Announces Strategic Investment Alliance to Combat Dementia Globally
Mar 17, 2015
PDF 8.8 KB Add to Briefcase
View Summary Phase 3 Study with IMBRUVICA® (ibrutinib) Combination Demonstrates Significant Delay in Disease Progression
Mar 16, 2015
PDF 62.4 KB Add to Briefcase
View Summary Findings to be Presented at Annual Scientific Session of the American College of Cardiology (ACC) About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO®
Mar 2, 2015
PDF 274.9 KB Add to Briefcase
View Summary Johnson & Johnson Announces Binding Offer from Cardinal Health to Acquire Cordis
Mar 2, 2015
PDF 8.3 KB Add to Briefcase
View Summary Johnson & Johnson Announces Patent and Trademark Office Action Related to REMICADE®
Feb 12, 2015
PDF 8.2 KB Add to Briefcase
View Summary Janssen Launches Three New Research Platforms Focused on Redefining Healthcare
Feb 12, 2015
PDF 13.3 KB Add to Briefcase
View Summary European Commission approves additional indication for VELCADE® (bortezomib) in mantle cell lymphoma
Feb 6, 2015
PDF 63.8 KB Add to Briefcase
View Summary U.S. FDA Grants Priority Review for YONDELIS® (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma
Feb 3, 2015
PDF 17.2 KB Add to Briefcase
View Summary PREZCOBIX™ (darunavir/cobicistat) Approved in the U.S. for the Treatment of Adults Living With HIV-1
Jan 29, 2015
PDF 20.8 KB Add to Briefcase
View Summary U.S. FDA Approves IMBRUVICA® (ibrutinib) for the Treatment of Waldenström's Macroglobulinemia: First FDA-Approved Therapy for This Disease
Jan 29, 2015
PDF 68.1 KB Add to Briefcase
View Summary Johnson & Johnson Reports 2014 Fourth-Quarter and Full-Year Results:
Jan 20, 2015
PDF 72.5 KB Add to Briefcase
View Summary FDA Grants Priority Review for Three-Month Paliperidone Palmitate for the Treatment of Schizophrenia
Jan 19, 2015
PDF 83.2 KB Add to Briefcase
View Summary Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative
Jan 16, 2015
PDF 18.5 KB Add to Briefcase
View Summary Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest U.S. License Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) Oral Solution
Jan 15, 2015
PDF 12.4 KB Add to Briefcase
View Summary Real-World Data Published in Clinical Cardiology Show Consistent Safety Performance of Once-Daily XARELTO®
Jan 14, 2015
PDF 301.8 KB Add to Briefcase
View Summary Johnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen
Jan 6, 2015
PDF 17.6 KB Add to Briefcase

= add release to Briefcase